$1.2B in 4 Months: Neurotechnology in 2026 so far …

1 May 2026

By Taylor Lyons

Image of a neuralink surgical implant

Last year I wrote about the past, present and future of neurotechnology. At the time, a lot of the “future” still felt a bit theoretical but that is no longer the case.

We’re only a few months into 2026 and the pace of progress is hard to ignore. The level of funding going into the space is huge, clinical trials are accelerating, and companies are starting to move from research into real-world application.

Here’s what’s actually happening:

The funding

The amount of capital flowing into neurotech this year is significant, here’s a snapshot:

Merge Labs – $250M+ raise (OpenAI-backed)
BrainCo Inc – $280M funding
Science Corp – $230M Series C
Cognito Therapeutics – $105M Series C
Beacon Biosignals – $97M+ Series B
Axoft – $55M Series A
Nervonik – $52.5M Series B
Cala Health – $50M growth capital
ONWARD Medical – €40M raise
Gestala – $20M+ seed

In total, that’s $1.2B+ invested in just the first four months of 2026, across a relatively small group of companies.

The clinical progress

This is where things stop being theoretical.

Neuralink – multiple human implants, patients controlling devices
Paradromics – advancing speech restoration trials
INBRAIN Neuroelectronics – first-in-human graphene implant completed
Motif Neurotech – FDA approval to begin human depression trials
CorTec – FDA Breakthrough for stroke rehabilitation
Axoft – already tested in 10+ patients

These are real patients and real outcomes. Not demos.

The collaborations

No company is building this alone anymore.

MintNeuro × Motif Neurotech
Chips + implants combined
Merge Labs × OpenAI
AI + neural decoding
Precision Neuroscience × Medtronic
Startup tech integrated into surgical systems
ClearPoint Neuro × adeor medical AG
Neurosurgical hardware system

What’s interesting is that even companies working in similar areas aren’t trying to do everything themselves. They’re partnering up.

I think that’s a good sign for the space. The stack is too complex, hardware, software, AI, clinical, for one company to realistically own it all. Instead of slowing things down trying to build everything internally, they’re working together to move faster. That’s probably part of why progress feels quicker this year than it did before.

What’s actually changing

Neurotechnology is becoming practical. It’s no longer just research, patients are actually benefiting.

The focus is now on real use cases like depression, stroke and chronic pain, with devices moving toward closed-loop systems that can sense and respond in real time.

The field is also splitting in two. Implant-based approaches like Neuralink offer precision, while non-invasive plays like Merge Labs aim to scale faster. Both are being heavily funded.

And when over $1.2B+ goes into the space in four months, that tells you everything you need to know about where this is heading.

Why it matters

This isn’t theoretical anymore.

Patients are already using these systems, companies are raising serious capital, and approvals are increasing. A year ago, this felt early. Now it feels like the start of something real.

And if this is what the first few months of 2026 look like, the pace from here is only going one way.

About the author

Taylor Lyons is a Recruitment Consultant at Aspire Life Sciences. He specialises in bridging the gap between talented professionals and leading companies within the MedTech sector across EMEA. With a strong focus on Medical Device Regulation (MDR), he takes a strategic approach to recruitment, ensuring both candidates and organisations are aligned across compliance, skillset, and long-term fit.

If you’re looking for a new opportunity or building a team in this space, feel free to reach out: taylor.lyons@aspirerecruitmentgroup.com